QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 leerink-partners-initiates-coverage-on-ibio-with-outperform-rating-announces-price-target-of-2

Leerink Partners analyst Roanna Ruiz initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price T...

 chardan-capital-maintains-buy-on-ibio-maintains-5-price-target

Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:IBIO) with a Buy and maintains $5 price target.

 ibio-announces-preclinical-data-in-which-an-engineered-amylin-receptor-agonist-antibody-reduced-acute-food-intake-in-a-mouse-model-of-obesity-by-60-equivalent-to-the-reduction-in-food-intake-from-a-clinically-advanced-dual-amylin-and-calcitonin-receptor-agonist-peptide-67

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparabl...

 us-stocks-likely-to-open-higher-after-trump-announces-iran-israel-ceasefire-fedex-td-synnex-in-focus-ahead-of-earnings

U.S. futures were trading higher on Tuesday after a positive day of trade on Monday. Futures of major benchmark indices were tr...

 ibio-announces-it-will-host--conference-call-on-tuesday-june-24-at-830-am-est-to-review-its-latest-advances-in-obesity-and-cardiometabolic-disease-treatments-and-announce-a-third-target-in-the-astralbio-collaboration-in-addition-to-myostatin-and-activin-e

Review of promising Myostatin and Activin E antibody dataiBio to announce 3rd target in Astral Bio CollaborationConference call...

 ibio-initiates-non-human-primate-study-for-its-activin-e-engineered-antibody-candidate-now-named-ibio-610-this-preclinical-study-will-evaluate-the-pharmacokinetics-and-early-signs-of-efficacy-of-ibio-610-in-obese-and-elderly-nhps-including-its-impact-on-fat-and-body-composition

iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibodyNew study aims to evaluate the half-l...

 chardan-capital-maintains-buy-on-ibio-maintains-5-price-target

Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:IBIO) with a Buy and maintains $5 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION